Lanreotide is a somatostatin analog. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Lanreotide has an FDA-approved product on the U.S. market, marketed as Lanreotide Acetate under application NDA215395.
The current label is held by Cipla USA Inc.
From the FDA label
anreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. 1.1 Acromegaly Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.Quoted from the FDA-approved prescribing information
The evidence
One source on Lanreotide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Lanreotide's FDA-approved label indicates it for acromegaly or for a growth disorder, which are assessed on this axis. These are the markers clinicians use when assessing the growth hormone axis. They are listed here so you can read about them, not as a statement that Lanreotide changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Lanreotide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides